AI-powered dog cancer vaccine startup Gamgee secures $4M in seed funding

Do you remember the story of the "real-life Good Samaritan" that went viral months ago?

An Australian AI expert with no professional background taught himself genomics to save his dog with terminal cancer, personally developing the world’s first custom mRNA cancer vaccine using ChatGPT and AlphaFold.

After one injection, a tennis-ball-sized tumor on the dog’s leg shrank by 75% miraculously, successfully extending its life.

However, the latest twist in the story caught everyone off guard and left them emotionally overwhelmed.

Today, Paul Conyngham announced a heartbreaking message: his beloved dog Rosie has crossed the rainbow bridge.

This isn't because the AI vaccine is ineffective, but because the pace of vaccine production couldn't keep up with death's advance.

Rosie ultimately passed away because a personalized mRNA cancer vaccine could not be produced quickly enough.

But the story doesn't end here.

Just now, Paul announced the official establishment of the startup Gamgee, which has completed a $4 million seed round led by Founders Fund and supported by Y Combinator.

Despite the loss of his own dog, this "father" is determined to develop clinically validated and scalable dog cancer vaccines for dogs worldwide.

In 2024, an 8-year-old Bull Terrier named Rosie was diagnosed with mast cell cancer, and the veterinarian said she had only months left.

Surgery, chemotherapy, immunotherapy... all methods failed. With 17 years of machine learning experience, Paul decided: I’ll save her my way!

Spending just $3,000 on DNA sequencing of tumors and healthy blood, Paul uploaded massive genomic data into his own program. He consulted ChatGPT for biological principles and used AlphaFold to create 3D models of mutated proteins, ultimately identifying a targeted attack point specific to Rosie’s tumor.

AlphaFold's 3D model of Rosie's cancer

Part of the code for creating mRNA therapy

He carried this AI-generated "vaccine formula," ran himself ragged, and finally convinced scientists at the University of New South Wales and the University of Queensland to synthesize a vaccine.

In December 2025, after the first dose was administered, a miracle occurred.

The large tumor on Rosie's leg shrank by 50%–75%.

Microscopic analysis revealed that large numbers of immune cells (macrophages and T cells) were aggressively attacking the cancer cells. Rosie regained her energy and was even able to leap over fences again, chasing rabbits.

The whole world is abuzz: personalized vaccines are within reach!

However, reality is far more brutal than the movies.

Cancer cells are too cunning—they mutated and developed drug resistance—Rosie’s cancer has returned.

At this moment, she urgently needs a second-generation mRNA vaccine customized for the latest variant.

However, the slow pace of traditional laboratories, cumbersome manual processes, and lengthy approval procedures did not allow Rosie to receive the vaccine in time.

“I lost my dog because we weren’t fast enough at developing the next mRNA cancer vaccine,” Paul wrote heartbrokenly.

As an ordinary person, even with knowledge of AI, rapidly customizing an mRNA vaccine within one or two months remains nearly impossible against the backdrop of the existing medical industry system.

I shouldn’t be the only person capable of doing this. Having a background in machine learning and months of round-the-clock work shouldn’t be a barrier to accessing life-saving medication.

Rosie has left, but the legacy she left behind has just begun to take root.

To prevent such a tragedy from happening again, Paul founded Gamgee, a name inspired by The Lord of the Rings.

Gamgee's vision is to cure cancer in dogs by bringing personalized mRNA cancer vaccines to dogs worldwide.

Currently, they have launched their first prototype of a personalized cancer treatment designed for dogs.

Founders Fund, founded by Peter Thiel, unhesitatingly led the $4 million seed round. A host of prominent figures, including global top accelerator YC, Loyal CEO Celine Halioua, and Dropbox co-founder Arash Ferdowsi, also joined in.

Why are top Silicon Valley VCs funding a project to "save dogs"?

Because what Gamgee aims to solve is the fatal challenge that led to Rosie's death: speed and cost.

Paul spent a full year and $20,000 to complete the entire process.

Now, Gamgee is turning this process into a SaaS industrialized production line.

They have built an end-to-end closed-loop platform. Ordinary dog owners no longer need to run around like Paul—you simply need to follow these steps.

1. Submit a tumor: Gamgee will send you a collection kit, and your veterinarian will collect samples of your dog’s tumor and healthy tissue and return them.

2. AI Lightning Decoding: Samples undergo direct DNA and RNA sequencing, and Gamgee’s software system takes over. AI algorithms precisely identify and organize cancer cell mutation targets worthy of intervention, while preserving evidence for every decision.

3. Vaccine Output: The system automatically generates the mRNA vaccine design ready for manufacturing. Gamgee coordinates production and cold-chain transportation until the veterinarian administers the customized vaccine to the dog.

Gamgee set a crazy KPI: target reducing vaccine design time to within 48 hours and lowering the end-to-end cost of the entire treatment to $2,000!

“Genome sequencing, protein modeling, mRNA synthesis—the tools are all there. What I built for Rosie isn’t new science, but a new way to access it,” said Paul.

This is truly a revolutionary medical breakthrough that is transforming the industry.

Cure 6 million dogs with cancer worldwide

In terms of business potential, Gamgee demonstrates a strong Silicon Valley-style "data flywheel" mindset.

First, why a dog?

This is an enormous and deeply urgent market.

In the United States alone, approximately 6 million dogs are diagnosed with cancer each year.

Cancer is the leading cause of death in adult dogs. Most dog owners have no choice but to spend thousands of dollars on painful treatments such as chemotherapy, radiation, or surgery.

More importantly, from both a biological and AI algorithm training perspective, dogs are the ideal subjects for validating personalized cancer vaccines.

They have a pure gene pool.

Many modern dog breeds were developed over the past few centuries from small, genetically isolated populations. This genetic concentration has made many breeds—such as Golden Retrievers and Labrador Retrievers—highly susceptible to specific types of cancer.

This makes it easier for AI to identify patterns in mutations.

Additionally, dogs develop cancer naturally, rather than being artificially induced as in laboratory mice. Their immune systems are fully intact, and their disease progression timelines are ideal for rapidly validating clinical efficacy.

The snowball effect of data is Gamgee's most core moat.

Currently, datasets on animal genomics and immune responses remain extremely scarce. With every dog treated, Gamgee collects a valuable dataset of “sequencing + immune response + clinical outcomes.”

Once this data flywheel starts spinning, it will become unstoppable.

Collect data → Optimize AI target selection model → Develop the next generation of more potent vaccines → Generate better therapeutic data → Attract more dog treatments.

A $4 million seed round has now launched clinical trials, with the first trials underway in Australia in collaboration with leading institutions such as the University of New South Wales and the University of Queensland.

The trial will enroll 30 dogs with cancer; eligible dogs will participate free of charge and receive a personalized vaccine.

Meanwhile, Gamgee has already accepted case registrations worldwide, with over 300 dogs on the waiting list.

But Gamgee's ambitions extend far beyond dogs.

For top investors, what they see is not just the pet healthcare market, but the dawn of 'N-of-1' medicine—extreme personalized care tailored to individual patients.

Gamgee's ultimate goal is to establish a better treatment model based on "N-of-1," transcending species boundaries to include humans.

Imagine this: If Gamgee could run the industrialized process of "tumor sequencing-AI design-48-hour mRNA vaccine synthesis" through thousands of dogs, this technology would soon benefit humans.

As David Thomas, Director of the Centre for Molecular Oncology at the University of New South Wales, said: “If we can do this in dogs, why not extend it to all humans with cancer?”

Currently, more than 1,600 cancer therapeutics and vaccines are under development worldwide, and the wave of mRNA technology and precision medicine has swept across the globe.

And just a few days ago, Moderna and Merck jointly announced—

The world’s first mRNA cancer therapy, deeply designed with AI involvement and personalized according to the gene mutations of a patient’s cancer cells, has achieved historic success in a global Phase III clinical trial for high-risk melanoma!

This process is literally the ultimate human version of Paul saving Rosie!

Same as removing tumor tissue for genetic sequencing; same as deploying an AI large model that rapidly simulates possibilities within hours, precisely identifying the 34 most potent personalized targets from thousands of mutations.

The latter therapy has significantly extended recurrence-free survival and markedly reduced the risk of tumor metastasis to distant sites such as the lungs, brain, and liver.

Moderna’s clinical success demonstrates that the pathway—tumor sequencing ➡️ AI selection of neoantigens ➡️ customized mRNA ➡️ immune activation—is fully viable against human cancers.

Clearly, we are on the brink of AI curing cancer.

Rosie never got to receive her second vaccine dose.

But her story gave hope to six million dogs diagnosed with cancer.

Paul ended his tweet announcing Gamgee’s funding with five words: “I love you, Rosie.”

We built Gamgee so that no other dog would ever have to wait for that delayed hope again.

Although Rosie has forever closed her eyes, the legacy she left behind may illuminate the lives of millions of dogs and even help humans overcome cancer.

References: https://www.gamgee.io/ https://x.com/paul_conyngham/status/2090502003449590254

https://x.com/paul_conyngham/status/2036940410363535823

This article is from the WeChat public account "New Intelligence Yuan," authored by ASI Revelation, edited by Aeneas.